Methods of using microRNA-26a to promote angiogenesis

Patent metadata

Field	Value
Publication number	US-9322015-B2
Application number	US-201214003886-A
Country	US
Kind code	B2
Filing date	Mar 9, 2012
Priority date	Mar 9, 2011
Publication date	Apr 26, 2016
Grant date	Apr 26, 2016

Abstract

Methods for promoting angiogenesis, and for diagnosing the presence or risk of developing disorders associated with impaired angiogenesis or blood flow to a tissue in the body, using microRNA-26a (miR-26a).

First claim

What is claimed is:

1. A method of promoting angiogenesis for treating a disorder associated with impaired angiogenesis or blood flow to a tissue in the body in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antagomir targeting microRNA-26a (miR-26a), wherein the antagomir is complementary to 7 or more nucleotides of mirR-26a and comprises the sequence ACTTGA (SEQ ID NO:5).

2. The method of claim 1 , wherein the inhibitory nucleic acid comprises one or more locked nucleotides.

3. The method of claim 1 , wherein the disorder is selected from the group consisting of ischemic heart disease, coronary artery disease, ischemic heart failure, peripheral artery disease (PAD), critical limb ischemia, and diabetic foot ulcers.

4. The method of claim 1 , wherein the subject is a human.

5. The method of claim 1 , wherein administering a therapeutically effective amount of an antagomir targeting microRNA-26a enhances angiogenesis in the subject.

6. The method of claim 5 , wherein angiogenesis is enhanced in cardiac tissues.

7. The method of claim 6 , wherein angiogenesis is enhanced in skeletal muscle.

8. The method of claim 1 , wherein the antagomir targeting microRNA-26a is administered intravenously.

Assignees

• Feinberg Mark W
• Icli Basak
• Brigham & Womens Hospital

Inventors

• Feinberg Mark W
• Icli Basak

Classifications

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C12N2310/141

  MicroRNAs, miRNAs · CPC title